CEL-SCI Corporation reported its financial results for the three months ended March 31, 2025, on May 14, 2025. The company recorded a net loss of $6.6 million for the quarter, compared to $7.2 million in the prior year period.
Basic and diluted net loss per common share increased to $0.08 for the three months ended March 31, 2025, compared to $0.14 for the prior year period. The company has instituted several cost-cutting measures, including reductions in salaries.
CEO Geert Kersten has been and is currently working without taking a salary, demonstrating his commitment to the company and Multikine’s potential to improve patient outcomes. The company plans to file for approval with Breakthrough Therapy Designation in Saudi Arabia based on completed Phase 3 results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.